Pre-made Pinatuzumab benchmark antibody ( Whole mAb ADC, anti-CD22 therapeutic antibody, Anti-SIGLEC2/SIGLEC-2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Pinatuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Pinatuzumab vedotin (DCDT2980S, FCU2703) is an anti-CD22 antibody-drug conjugate (ADC) developed by Genentech/ Hoffmann-La Roche for the treatment of diffuse large B-cell lymphoma (DLBCL). ... Pinatuzumab vedotin has proved its efficacy in inducing a complete tumor regression in xenograft lymphoma models.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-444-1mg	1mg	4635
GMP-Bios-ab-444-10mg	10mg	Inquiry
GMP-Bios-ab-444-100mg	100mg	Inquiry
GMP-Bios-ab-444-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Pinatuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody
INN Name	Pinatuzumab
Target	CD22
Format	Whole mAb ADC
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	6and:HL
95-98% SI Structure	None
Year Proposed	2012
Year Recommended	2013
Companies	Genentech
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma
Development Tech	na